Regulus reports 4Q loss

SAN DIEGO (AP) _ Regulus Therapeutics Inc. (RGLS) on Wednesday reported a loss of $14.4 million in its fourth quarter.

The San Diego-based company said it had a loss of 14 cents per share.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The biopharmaceutical company posted revenue of $18,000 in the period.

For the year, the company reported that its loss narrowed to $71.9 million, or 96 cents per share. Revenue was reported as $72,000.

In the final minutes of trading on Wednesday, the company's shares hit $1.26. A year ago, they were trading at $1.15.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RGLS at https://www.zacks.com/ap/RGLS